Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-07-20 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a notification to the stock exchange regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It references Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations for listed companies. The content is about the allotment of shares and the resulting increase in issued and paid-up capital. This fits the category of Share Issue/Capital Change announcements, as it details a change in the company's capital structure due to share allotment. The document is short and does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Interim Report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2021-07-20 English
Submission of the Integrated Report of the Company for the year ended March 31, 2021 along with the Notice dated July 8, 2021, convening the Thirty-Ninth Annual General Meeting of the Company, ....
AGM Information Classification · 95% confidence The document is a letter addressed to stock exchanges and regulatory bodies referencing compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It encloses the Integrated Report for the year ended March 31, 2021, and the Notice of the Thirty-Ninth Annual General Meeting (AGM) scheduled for August 11, 2021. The text includes the AGM Notice with detailed agenda items such as adoption of audited financial statements, dividend declaration, re-appointment of directors and auditors, and approval of an employee stock option plan. The document is not the full annual report but an announcement enclosing the report and the AGM notice. It is lengthy (15,000 characters) but primarily serves as a notification and invitation to the AGM along with the Integrated Report. According to the "Menu vs Meal" rule, since it states the report is enclosed and the AGM notice is included, this is best classified as AGM Information (AGM-R).
2021-07-17 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal communication addressed to stock exchanges and regulatory bodies regarding the upcoming Thirty-Ninth Annual General Meeting (AGM) of Lupin Limited. It details the record date for dividend entitlement, the remote e-voting process, and the schedule of voting events. The content focuses on procedural and regulatory compliance related to the AGM, including voting rights and dividend payment logistics. There is no financial data, management discussion, or detailed report content. The document serves as an announcement related to the AGM and voting procedures rather than the AGM report or minutes themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly AGM Information (AGM-R). However, since it primarily concerns the record date for dividend and remote e-voting facility for the AGM, it aligns best with Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7304 characters) and content confirm it is not a full report but an announcement related to voting and dividend record date.
2021-07-15 English
Please find attached intimation letter in respect of Annual General Meeting of Shareholders of Lupin Limited, to be held on Aug 11, 2021.
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal communication from Lupin Limited to stock exchanges and regulatory bodies regarding the upcoming Thirty-Ninth Annual General Meeting (AGM). It details the record date for dividend payment, the remote e-voting process, and the schedule of voting events related to the AGM. The document references compliance with SEBI Listing Regulations and the Companies Act, and it provides logistical information about the AGM and voting rights. There are no financial statements or detailed financial performance data included. The document is primarily an announcement about the AGM logistics, voting procedures, and dividend record date, not the AGM report or results themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly AGM Information (AGM-R). However, since it focuses on the record date for dividend and remote e-voting facility for the AGM, it is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 7397 characters, which is consistent with a detailed announcement rather than a full report.
2021-07-15 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Tavaborole Topical Solution) in the U.S. following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is short (3859 characters) and it is clearly a disclosure announcement rather than a detailed report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-13 English
Lupin Launches Tavaborole Topical Solution in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Tavaborole Topical Solution) in the U.S. following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is 3862 characters, which is relatively short and typical for a press release. There is no detailed financial data, no voting results, no management changes, no audit information, and no regulatory filing beyond the disclosure of a product launch. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2021-07-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.